Market Place
Sourcing Support
Vor Bio Discloses Inducement Grant Per Nasdaq LR 5635(C)(4)
01 Apr 2026 //
GLOBENEWSWIRE
Vor Bio Reports 2025 Financial Results And Corporate Update
30 Mar 2026 //
GLOBENEWSWIRE
Vor Bio Initiates Global Ph 3 Trial For Telitacicept in Sjögren
30 Mar 2026 //
GLOBENEWSWIRE
Vor Bio Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
23 Mar 2026 //
GLOBENEWSWIRE
Vor Bio To Join 46th TD Cowen Health Care Conference
23 Feb 2026 //
GLOBENEWSWIRE
Vor Bio To Present At 44th J.P. Morgan Healthcare Conference
06 Jan 2026 //
GLOBENEWSWIRE
Vor Bio Names Levin, Joustra to Board of Directors
23 Dec 2025 //
GLOBENEWSWIRE
Vor Bio Announces $150 Million Private Placement
15 Dec 2025 //
GLOBENEWSWIRE
Vor Bio Reports Q3 2025 Financials & Corporate Update
13 Nov 2025 //
GLOBENEWSWIRE
Vor Bio Plans $100M Public Stock Offering
10 Nov 2025 //
GLOBENEWSWIRE
Telitacicept Hits Primary Endpoint In Ph3 IgA Nephropathy Study
08 Nov 2025 //
GLOBENEWSWIRE
Vor Bio To Participate In Upcoming Investor Conferences
07 Nov 2025 //
GLOBENEWSWIRE
Vor Bio Appoints Jeremy Sokolove, M.D. As Chief Medical Officer
03 Nov 2025 //
GLOBENEWSWIRE
Vor Bio Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
31 Oct 2025 //
GLOBENEWSWIRE
Telitacicept Shows Long-Term Efficacy In 48-Week China Ph 3 Data
29 Oct 2025 //
GLOBENEWSWIRE
Vor Bio to Host Webcast on China Ph3 Telitacicept Sjögren’s Data
22 Oct 2025 //
GLOBENEWSWIRE
Vor Bio Presents China Phase 3 Iga Nephropathy Study At ASN
17 Oct 2025 //
GLOBENEWSWIRE
Vor Bio Publishes China Phase 3 Telitacicept Study In Lupus
16 Oct 2025 //
GLOBENEWSWIRE
Telitacicept Show Significant ESSDAI Impact in China Ph3 ACR 2025
14 Oct 2025 //
GLOBENEWSWIRE
Vor Bio Discloses Inducement Grants Per Nasdaq Lr 5635(C)(4)
03 Oct 2025 //
GLOBENEWSWIRE
Vor Bio Presents Phase 3 Sjögren`s Disease Study Poster At ACR
29 Sep 2025 //
GLOBENEWSWIRE
Vor Bio Appoints Navid Z. Khan as Chief Medical Affairs Officer
23 Sep 2025 //
GLOBENEWSWIRE
Vor Bio Presents 48-Week China Ph 3 Myasthenia Gravis Study
17 Sep 2025 //
GLOBENEWSWIRE
Vor Bio Joins Stifel 2025 Virtual Immunology, Inflammation Forum
12 Sep 2025 //
GLOBENEWSWIRE
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
02 Sep 2025 //
GLOBENEWSWIRE
RemeGen`s Telitacicept Result sets up IgAN Submission in China
28 Aug 2025 //
FIERCE PHARMA
Ex-Sarepta Exec Lands at Vor Bio as Commercial Chief
07 Aug 2025 //
FIERCE PHARMA
Vor Bio Names Dallan Murray Chief Commercial Officer in Biotech
04 Aug 2025 //
GLOBENEWSWIRE
Vor Bio Adds Biotech Leaders Cumbo, Detheux to Board
21 Jul 2025 //
GLOBENEWSWIRE
Vor Bio Grants Inducement Under Nasdaq Listing Rule 5635(c)(4)
18 Jul 2025 //
GLOBENEWSWIRE
Vor Bio Names Sandy Mahatme CFO and Chief Business Officer
10 Jul 2025 //
GLOBENEWSWIRE
Vor Bio Receives Grant Under Nasdaq Rule 5635(c)(4)
01 Jul 2025 //
GLOBENEWSWIRE
Vor Bio`s surprise $4B revival Vor Biosplits investor reactions
28 Jun 2025 //
ENDPTS
Vor Bio Announces $175 Million Private Placement
25 Jun 2025 //
GLOBENEWSWIRE
Vor Bio to wind down, laying off most staff
08 May 2025 //
FIERCE BIOTECH
Vor Bio Reports Q4 and Full Year 2024 Financial Results
20 Mar 2025 //
GLOBENEWSWIRE
Vor Bio Presents Research on Cell & Gene Therapy Trial & Challenges
13 Feb 2025 //
GLOBENEWSWIRE
Vor Bio to Participate in Oppenheimer Annual Healthcare Conference
03 Feb 2025 //
GLOBENEWSWIRE
Vor Bio`s Clinical Update on Shielded Transplants & FDA Feedback
09 Dec 2024 //
GLOBENEWSWIRE
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
12 Nov 2024 //
GLOBENEWSWIRE
New Data Validates Vor Bio`s Shielded Transplants Approach
05 Sep 2024 //
GLOBENEWSWIRE
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
17 Jan 2024 //
GLOBENEWSWIRE
Vor Bio`s dual stem cell, ADC shows consistent engraftment
10 Nov 2023 //
FIERCE BIOTECH
Primary Engraftment of Trem-cel in AML Patients Shows Promise of Vor`s Platform
09 Jun 2023 //
GLOBENEWSWIRE
Vor Biopharma heralds proof of concept for its gene-edited stem cells
16 Feb 2023 //
ENDPTS
Vor to Present Data from First Patient Treated with Trem-cel at 2023 Meetings
19 Jan 2023 //
GLOBENEWSWIRE
